2022 DECEMBER

Liver imaging and transporters

Biomed Pharmacother. 2022 Dec;156:113994. [¹¹C]glyburide PET imaging for quantitative determination of the importance of Organic Anion-Transporting Polypeptide transporter function in the human liver and whole-body. Marie S, Breuil L, Chalampalakis Z, Becquemont L, Verstuyft C, Lecoq AL, Caillé F, Gervais P, Lebon V, Comtat C, Bottlaender M, Tournier N. PubMed

Transporter structure

Nat Commun. 2022;13:6714. Structural basis of organic cation transporter-3 inhibition. Khanppnavar B, Maier J, Herborg F, Gradisch R, Lazzarin E, Luethi D, Yang JW, Qi C, Holy M, Jäntsch K, Kudlacek O, Schicker K, Werge T, Gether U, Stockner T, Korkhov VM, Sitte HH. PubMed

Pharmacogenetics of transporters

Clin Pharmacol Ther. 2022;In press. Prescriber adoption of SLCO1B1 genotype-guided Simvastatin clinical decision support in a clinical pharmacogenetics program. Owusu Obeng A, Scott SA, Kaszemacher T, Ellis SB, Mejia A, Gomez A, Nadukuru R, Abul-Husn NS, Vega A, Waite E, Gottesman O, Cho J, Bottinger EP. PubMed

Drug Metab Pharmacokinet. 2022;47:100470. Comparison of the transport kinetics of fexofenadine and its pH dependency among OATP1A2 genetic variants. Han H, Takeshi Akiyoshi, T, Morita T, Kataoka H, Katayama  K, Yajima K ,Imaoka A, Ohtani H. PubMed

Drug Metab Pharmacokinet. 2022;47:100473. Drug transporters are implicated in the diffusion of tacrolimus into the T lymphocyte in kidney and liver transplant recipients: Genetic, mRNA, protein expression, and functionality. Coste G, Robin F, Chemouny J, Tron C, Le Priol J, Bouvet R, Le Vée M, Houssel-Debry P, Rayar M, Verdier MC, Roussel M, Galibert MD, Bardou-Jacquet E, Fardel O, Vigneau C, Boudjema K, Laviolle B, Lemaitre F. PubMed

Pharmacogenet Genomics. 2023;33:10-18. Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. Keller DN, Medwid SJ, Ross CD, Wigle TJ, Kim RB. PubMed

Biomed Pharmacother. 2022;156:113914. A physiologically based pharmacokinetic model for open acid and lactone forms of atorvastatin and metabolites to assess the drug-gene interaction with SLCO1B1 polymorphisms. Reig-López J, Merino-Sanjuan M, García-Arieta A, Mangas-Sanjuán V. PubMed

Int J Mol Sci. 2022;23:7468. Hepatic expression of the Na⁺-Taurocholate Cotransporting Polypeptide is independent from genetic variation. Tremmel R, Nies AT, van Eijck BAC, Handin N, Haag M, Winter S, Büttner FA, Kölz C, Klein F, Mazzola P, Hofmann U, Klein K, Hoffmann P, Nöthen MM, Gaugaz FZ, Artursson P, Schwab M, Schaeffeler E. PubMed

Transporter function

Eur J Pharm Sci. 2022;In press. Kaempferol suppression of acute colitis is regulated by the efflux transporters BCRP and MRP2. Liu Y, Lu Y, Li X, Zhang Z, Sun L, Wang Y, He Z, Liu Z, Zhu L, Fu L. PubMed

Front Pharmacol. 2022 Sep 29;13:946360. Kaempferol attenuates nonalcoholic steatohepatitis by regulating serum and liver bile acid metabolism. Lu Y, Shao M, Zhang C, Xiang H, Wang J, Wu T, Ji G. PubMed

Front Med (Lausanne). 2022;8:800421.The Role of NF-kB in the downregulation of Organic Cation Transporter 2 expression and renal cation secretion in kidney disease. Han C, Zheng J, Wang F, Lu Q, Chen Q, Hu A, Visentin M, Kullak-Ublick GA, Gai Z, Chu L. PubMed

Biomolecules. 2022;12:1664. Atypical substrates of the Organic Cation Transporter 1. Redeker KM, Jensen O, Gebauer L, Meyer-Tönnies MJ, Brockmöller J. PubMed

Drug Metab Dispos. 2022;In press. Renal transporter alterations in patients with chronic liver diseases: Nonalcoholic Steatohepatitis, alcohol-associated, viral hepatitis, and alcohol-viral combination. Frost KL, Jilek JL, Sinari S, Klein RR, Billheimer D, Wright SH, Cherrington NJ. PubMed

Transporters and liver injury

JHEP Rep. 2022;4:100573. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice. Kunst RF, de Waart DR, Wolters F, Duijst S, Vogels EW, Bolt I, Verheij J, Beuers U, Oude Elferink RPJ, van de Graaf SFJ. PubMed

Liver Int. 2022;In press. A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry. Björnsson ES, Stephens C, Atallah E, Robles-Diaz M, Alvarez-Alvarez I, Gerbes A, Weber S, Stirnimann G, Kullak-Ublick G, Cortez-Pinto H, Grove JI, Lucena MI, Andrade RJ, Aithal GP. PubMed

Toxicol Lett. 2022;368:33-46. In vitro/in silico prediction of drug induced steatosis in relation to oral doses and blood concentrations by the Nile Red assay. Brecklinghaus T, Albrecht W, Duda J, Kappenberg F, Gründler L, Edlund K, Marchan R, Ghallab A, Cadenas C, Rieck A, Vartak N, Tolosa L, Castell JV, Gardner I, Halilbasic E, Trauner M, Ullrich A, Zeigerer A, Demirci Turgunbayer Ö, Damm G, Seehofer D, Rahnenführer J, Hengstler JG. PubMed

J Hepatol. 2022;77:71-83. Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity. Ghallab A, Hassan R, Hofmann U, Friebel A, Hobloss Z, Brackhagen L, Begher-Tibbe B, Myllys M, Reinders J, Overbeck N, Sezgin S, Zühlke S, Seddek AL, Murad W, Brecklinghaus T, Kappenberg F, Rahnenführer J, González D, Goldring C, Copple IM, Marchan R, Longerich T, Vucur M, Luedde T, Urban S, Canbay A, Schreiter T, Trauner M, Akakpo JY, Olyaee M, Curry SC, Sowa JP, Jaeschke H, Hoehme S, Hengstler JG. PubMed

Reviews

J Intern Med. 2022;292:190-204. Current treatment of non-alcoholic fatty liver disease. Paternostro R, Trauner M. PubMed

Eur J Drug Metab Pharmacokinet. 2022; In press. Hepatic transporters alternations associated with Non-alcoholic Fatty Liver Disease (NAFLD): A systematic review. Omidkhoda N, Zare S, Mahdiani S, Samadi S, Akhlaghi F, Mohammadpour AH. PubMed

Nat Rev Gastroenterol Hepatol. 2022;19:432-450. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Fuchs CD, Trauner M. PubMed

Gut. 2022;71:194-209. Novel therapeutic targets for cholestatic and fatty liver disease. Trauner M, Fuchs CD. PubMed

Acta Pharm Sin B. 2022;12:2751-2777. Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Lai Y, Chu X, Di L, Gao W, Guo Y, Liu X, Lu C, Mao J, Shen H, Tang H, Xia CQ, Zhang L, Ding X. PubMed

Life Sci. 2022 Dec 1;310:121109. Advances in understanding the regulatory mechanism of organic solute transporter α-β. Lu ZN, He HW, Zhang N. PubMed

DDI

CPT Pharmacometrics Syst Pharmacol. 2022;In press. Physiologically-based pharmacokinetic modeling for primary metabolites of CYP3A and P-glycoprotein inhibitors in drug-drug interactions: Should we assume the free drug hypothesis? Yamazaki S, Evers R, De Zwart L. PubMed

Pharmacol Ther. 2022 Oct;238:108271. The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans. Storelli F, Yin M, Kumar AR, Ladumor MK, Evers R, Chothe PP, Enogieru OJ, Liang X, Lai Y, Unadkat JD. PubMed

Drug Metab Dispos. 2022;50:1472-1482. Human pharmacokinetics of LYS006, an oral leukotriene A4 hydrolase inhibitor displaying target-mediated drug disposition. Poller B, Pearson D, Leuthold LA, Fink M, Jullion A, Schweigler P, Tor Carreras E, Marvalin C, Loesche C, Weiss HM. PubMed

J Med Chem. 2022;65:14578-14588. Identification of Organic Anion Transporter 2 inhibitors: Screening, structure-based analysis, and clinical drug Interaction risk assessment. Ryu S, Woody N, Chang G, Mathialagan S, Varma MVS. PubMed

Front Pharmacol. 2022 Oct 25;13:1033667. Pharmacokinetic herb-drug interactions: Altered systemic exposure and tissue distribution of ciprofloxacin, a substrate of multiple transporters, after combined treatment with Polygonum capitatum Buch.-Ham. ex D. Don extracts. Li Z, Du X, Tian S, Fan S, Zuo X, Li Y, Wang R, Wang B, Huang Y. PubMed

Biopharm Drug Dispos. 2022;In press. Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells. Le Vée M, Moreau A, Jouan E, Denizot C, Parmentier Y, Fardel O. PubMed

Molecules. 2022;27:6815. Itraconazole-induced increases in Gilteritinib exposure are mediated by CYP3A and OATP1B. Garrison DA, Jin Y, Talebi Z, Hu S, Sparreboom A, Baker SD, Eisenmann ED. PubMed

Pharmaceutics. 2022;14:1933. A metabolomics approach for predicting OATP1B-type transporter-mediated Drug-Drug Interaction liabilities. Li Y, Jin Y, Taheri H, Schmidt KT, Gibson AA, Buck SAJ, Eisenmann ED, Mathijssen RHJ, Figg WD, Baker SD, Sparreboom A, Hu S. PubMed

J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1210:123437.Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method. Jin Y, Li Y, Eisenmann ED, Figg WD, Baker SD, Sparreboom A, Hu S. PubMed

Experimental models

Biopreserv Biobank. 2022;In press. Cold preservation of human hepatocytes with high viability. Lee SML, Kern A, Jauch KW, Thasler R, Niess H, Thasler WE. PubMed

FEBS Lett. 2022;596:1445-1452. Lipidomics profiles in hepatocytes from nonalcoholic steatohepatitis patients differ markedly from in vitro-induced steatotic hepatocytes. Kralj T, Khatri R, Brouwer KR, Brouwer KLR, Creek DJ. PubMed

Sci Rep. 2022;12:14333. A novel differentiated HuH-7 cell model to examine bile acid metabolism, transport and cholestatic hepatotoxicity. Saran C, Fu D, Ho H, Klein A, Fallon JK, Honkakoski P, Brouwer KLR. PubMed